Tenax Therapeutics Achieves Phase 3 Enrollment Target, Initiates Second Pivotal Trial, and Secures Funding Through 2027

summarizeSummary

Tenax Therapeutics announced significant progress in its Phase 3 clinical program for TNX-103, achieving the randomization target for the LEVEL study and initiating a second pivotal trial, while also reporting a strong cash position expected to fund operations through 2027.

check_boxKey Events

• Phase 3 LEVEL Study Achieves Randomization Target

  Tenax Therapeutics announced it has achieved its randomization target of 230 patients in the Phase 3 LEVEL study for TNX-103, with topline data expected in the third quarter of 2026. The screening period for the study has now closed.

• Initiation of Second Global Phase 3 Trial (LEVEL-2)

  The company initiated LEVEL-2, a global and second registrational Phase 3 clinical trial of TNX-103 in patients with PH-HFpEF, and also opened a long-term open-label extension (OLE) study.

• Strong Cash Position and Extended Runway

  Tenax reported cash and cash equivalents of $97.6 million as of December 31, 2025, which is expected to fund the company's operations through 2027.

• Expanded Patent Protection for TNX-103

  In January 2026, the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance expanding protection to cover any subcutaneous formulation of levosimendan (TNX-103) for a broad range of indications, including PH-HFpEF.

auto_awesomeAnalysis

This filing is highly significant for Tenax Therapeutics, a development-stage pharmaceutical company. Achieving the randomization target for the pivotal Phase 3 LEVEL study is a major de-risking milestone, bringing the company closer to potential commercialization with topline data expected in Q3 2026. The initiation of a second global Phase 3 trial (LEVEL-2) further demonstrates robust pipeline progression and commitment to addressing PH-HFpEF, a condition with no approved treatments. Coupled with a strong cash position of $97.6 million, providing an operational runway through 2027, the company has significantly enhanced its financial stability and reduced near-term financing risk. The expanded patent protection for TNX-103 also strengthens its long-term market potential. While the company reported a widened net loss, this is expected for a biotech heavily investing in late-stage clinical trials, and the substantial cash balance mitigates concerns.